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Syndromic management of sexually transmitted infections (STIs) using algorithms based on 
the patient's presenting symptoms has been the cornerstone of STI care in many low/middle-
income nations for over three decades; usually because of limited resources and lack of 
adequate laboratory services and also to deliver care as quickly as possible. The 
shortcomings of this approach have been well documented and include the inability to detect 
asymptomatic STIs,1 the lack of antibiotic susceptibility testing, the poor positive predictive 
value (PPV) of syndromic treatment resulting in the overuse of antibiotics (of particular 
concern in relation to antibiotic resistance to gonorrhoea)2 and limited opportunities for 
surveillance and partner notification. Of the three main STI syndromes (vaginal discharge, 
urethral discharge in men and genital ulceration), vaginal discharge has the lowest PPV for a 
laboratory diagnosable STI. Without adequate partner notification and treatment, the source 
partner is often rapidly reinfected. At a population level, asymptomatic STIs constitute the 
majority of those infected3 and the inability to test and treat these individuals means that 
most infected individuals remain untreated, resulting in long-term clinical complications and 
ongoing transmission.
As an example, South Africa introduced STI syndromic management in 1995 and has 
followed WHO guidance including the recommendation that national guidelines should be 
regularly evaluated with periodic aetiological and antimicrobial resistance surveys and 
antibiotic treatment adjusted accordingly.4 However, training and implementation are often 
poor.5 A study in rural KwaZulu-Natal (KZN), in the epicentre of the HIV epidemic, 
estimated that the overall effectiveness of syndromic STI services to successfully treat 
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curable symptomatic episodes was only 13.1% (95% CI 8.9% to 17.8%), and that the 
prevalence of gonorrhoea and chlamydia has not fallen since the introduction of syndromic 
management.6
Perhaps the most concerning aspect of ongoing STI syndromic management, is that this 
approach continues to be used in many HIV high-prevalence countries, despite the 
recognition of the strong epidemiological and biological links between STIs and HIV.7 
Furthermore, the overwhelming economic and service burden of HIV in some sub-Saharan 
countries has further exacerbated poor and inadequate STI care. Moreover, virtually all sub-
Saharan countries have systems in place to collect detailed HIV epidemiological data, 
whereas STI data is usually limited to numbers of patients presenting with STI symptoms to 
the small number of available public STI services, leaving healthcare providers with limited 
information about the incidence and prevalence of STIs.
Studies at the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 
have shown a high prevalence of laboratory-diagnosed STIs in women at the time of acute 
HIV infection (over 25% had at least one STI) and that clinical assessment alone missed 
88% of laboratory-diagnosed STIs. In addition, elevation in inflammatory genital tract 
cytokines, a possible marker of HIV acquisition, was shown to be just as likely in women 
with or without STI-related symptoms,8 further strengthening the argument that without 
diagnostic testing the impact of STIs on HIV transmission will continue unabated. In 
addition, bacterial vaginosis, which is very common in many young women in KZN is also 
associated with elevated inflammatory cytokines and increased HIV acquisition.
Improving economic conditions in some low/middle-income nations, more trained 
healthcare workers, and the prospect of reliable, relatively cheap, simple, automated point-
of-care STI testing and the possible use of expedited partner therapy (EPT), where the 
patient is provided with treatment or a prescription for their sexual partner(s), have prompted 
a rethink of this model.9 In response, in January 2016, a workshop was held at CAPRISA. 
The goal of this workshop was to assemble key stakeholders involved in STI care or policy 
development to evaluate the current STI epidemic and care provision in KZN and to discuss 
the latest evidence for and against the transition to a diagnostic care model. Among the 
matters considered were the latest local epidemiology and long-term complications of STIs; 
the association of genital tract inflammatory cytokines with STIs and HIV acquisition; 
point-of-care tests and other recent diagnostic advances; and partner notification including 
the possible implementation and problems with EPT.
Despite initial concerns about the legality of EPT, this approach is increasingly being used in 
the UK, the USA and Australia particularly for chlamydial infection. Studies have shown 
that it is well accepted by patients and healthcare providers and can reduce the risk of 
chlamydial reinfection in women by 20%–29%.10 In contrast, in many communities in 
South Africa, women have low power within relationships and intimate partner violence 
(IPV) is common and these factors will need to be carefully considered before EPT can be 
appraised. Fundamentally transforming gender relationships, engaging male partners and 
providing women with additional skills to reduce the IPV are essential for EPT 
implementation.
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Among a plethora of new point-of-care assays for chlamydia and gonorrhoea, the combined 
Xpert CT/NG (Cepheid, Sunnydale, California, USA) stands out due to its high sensitivity 
and specificity,11 and the available GeneXpert infrastructure that already exists for the rapid 
diagnosis of tuberculosis in South Africa. In addition, a GeneXpert assay for Trichomonas 
vaginalis (TV) has recently been developed. CAPRISA has now introduced screening for 
STIs in its studies with the Xpert CT/NG and the Osom rapid TV antigen assays (Sekisui 
Diagnostics, Lexington, Massachusetts, USA) providing rapid results at an affordable cost.11 
In the future, these assays could be replaced by multiplex arrays, for example, the Randox 
STI Multiplex Array (Randox Laboratories, Crumlin, UK), to test for multiple organisms 
with a single sample close to patient care. Considering the large population of sexually 
active people potentially requiring access to diagnostic care, an alternative strategy would be 
to provide laboratory-based high-throughput Openarray testing (eg, Thermo Fisher 
Scientific, Waltham, Massachusetts, USA).12 These technologies are still being optimised, 
but could potentially allow for the testing of thousands of self-collected samples at a fraction 
of the cost.
One of the hallmarks of STI diagnosis in the developed world has been the use of 
microscopy from genital secretions supplemented by culture and sensitivity testing. This 
technology also existed in the developing world including South Africa, but unfortunately 
few technicians retain these skills, with the introduction of syndromic management partially 
to blame. Perhaps it would be conceivable to resurrect cheap and trusted microscopy 
services and marry them with new point-of-care technology.
How do we bring all these elements together to develop a workable diagnostic care model? 
First, all stakeholders, including healthcare providers, laboratories, patient advocacy groups, 
local and central governments, the WHO, interested research and non-governmental 
organisations and technology companies need to engage. Next, the most promising point-of-
care tests and technologies need to be carefully and systematically tested in a variety of 
urban and rural settings, to evaluate sensitivity and specificity, patient and healthcare worker 
acceptability, cost, ease or problems with implementation and the reliability and durability 
of equipment. In areas where HIV and tuberculosis are major public health problems the 
possible sharing of technology, such as the GeneXpert system should be considered. 
Similarly, EPT will need careful and systematic evaluation. Once this has been done, new 
algorithms will need to be developed and evaluated, if possible, with the help of the WHO.
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